Research using next-generation sequencing data and clinical records from HNSCC patients found that combining MATH with HPV status is an effective marker of improved patient outcome. High tumor MATH at surgery is associated with poor outcomes, while HPV-positive patients have lower average MATH values than HPV-negative patients.
The new guideline aims to reduce unnecessary re-excision rates by identifying optimal margin widths that minimize ipsilateral breast tumor recurrence. Wider margin widths do not significantly lower the risk, and the choice of radiation technique should not depend on margin width.
A comprehensive review of Medicare claims found that nearly all the increase in IMRT for prostate cancer was due to self-referral, leading to unnecessary radiation therapy. Self-referring urologists increased IMRT use by 146%, while non-self-referrers remained unchanged.
Researchers found that unstable chromosomes with breaks at common fragile sites are associated with a less favorable response to radiation therapy and surgery in prostate cancer patients. These abnormalities are often linked to DNA instability, which is characteristic of cancer cells.
A study of Stage T1aN0 breast cancer patients found no significant increase in deaths from cardiac disease or secondary malignancies among those receiving external beam radiation therapy (XRT). Women who received XRT had better survival rates and fewer deaths from all causes compared to non-XRT groups.
The study found a significantly lower quality of life in patients who received high-dose radiation therapy (74 Gy) compared to those receiving standard dose (60 Gy). IMRT was associated with a lower decline in QOL compared to 3-D CRT, even a year after treatment.
A secondary analysis of the historic RTOG 9202 prostate cancer trial found no additional benefits with long-term hormonal therapy compared to short-term therapy in intermediate-risk patients. The study suggests that administering less treatment can reduce side effects and healthcare costs without compromising survival rates.
A study found that avoiding specific regions of the brain during whole-brain radiotherapy prevents memory loss in patients. Limiting radiation to the hippocampus, a sensitive area for memory function, preserved memory function for up to six months after treatment.
A two-item questionnaire, including PHQ-9 and PHQ-2, effectively screened for depression in radiation therapy patients. The study found that these questions were as useful as the entire PHQ-9 in identifying depression, with an area under the curve of approximately 0.83.
A shorter course of androgen suppression therapy prior to radiation therapy yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients. The study confirmed a disease-specific-survival rate of 95 percent when patients received fewer weeks of neoadjuvant total androgen suppression.
A study by American Society for Radiation Oncology found that proton therapy can prevent costly side effects in children with medulloblastoma, making it both cost-effective and cost-saving compared to photon therapy. Proton therapy reduced the risk of hearing loss, secondary malignancy, and heart failure.
A multi-institutional study found that sulfasalazine does not reduce diarrhea in patients receiving pelvic radiation therapy, and may even increase the risk. The study, which enrolled 87 patients, used a randomized, double-blind, placebo-controlled design to evaluate the effectiveness of sulfasalazine versus placebo.
A randomized controlled trial of 147 women with stage IIIB cervical cancer found that adding cisplatin to radiation therapy and high-dose-rate brachytherapy improved disease-free survival and reduced late toxicity, while maintaining acceptable acute toxicity levels.
Patients under 50 years old have improved OS after SRS, with no greater risk of new brain metastases. SRS alone is a favorable first-line therapeutic option for younger patients.
The ASTRO/AUA joint guideline offers clinical principles and recommendations for radiation therapy use in patients with and without evidence of prostate cancer recurrence. The guideline is based on a comprehensive review of 324 research articles and provides detailed efficacy data for patients with detectable and undetectable PSA levels.
A study of 70 pediatric patients treated with proton therapy found high local control rates (83%) and overall survival (95%), with subtotal resection correlated to decreased cognitive and endocrine outcomes. Few patients developed growth hormone deficiency, hypothyroidism or hearing loss.
The Cancer Foundation of Northeast Georgia and the South Georgia Medical Center, Pearlman Cancer Center will each receive $8,000 to provide direct support for their organization's work supporting cancer patients. The grants also aim to raise awareness about the financial challenges faced by cancer patients.
Sherri Graves Smith, a cancer survivor and volunteer, will receive the 2013 Survivor Circle Award from ASTRO. She has dedicated her time and energy to helping others in her community, providing financial assistance and support to cancer patients struggling with daily living essentials.
Jean B. Owen, PhD, receives the highest honor from ASTRO for her extensive work in establishing and analyzing benchmarks for optimal care in radiation oncology. Her contributions include developing clinical performance measures and survey processes to improve quality of care nationwide.
The American Society for Radiation Oncology (ASTRO) has selected 10 outstanding members to receive the Fellow of ASTRO designation. These distinguished individuals have made substantial contributions to the field of radiation oncology through research, education, patient care, and leadership.
The American Society for Radiation Oncology (ASTRO) awarded a total of $34,500 to 42 researchers selected for the 2013 Annual Meeting Abstract Awards. The awards recognized outstanding abstracts in seven categories and honored top-rated research in radiation and cancer biology, clinical practice, and radiation physics.
ASTRO has awarded Amato Giaccia, Radhe Mohan, and Prabhakar Tripuraneni with the Society's highest honor—the ASTRO Gold Medal. The awardees have made outstanding contributions to radiation oncology through research, clinical care, teaching, and service.
A study found that radiation oncology received only 1.6% of the $30.9 billion in NIH-funded grants for cancer research in FY 2013. This disparity highlights an urgent need for increased funding to improve patient survival and treatment outcomes.
The new guideline provides detailed direction on treatment options for prostate cancer patients, including adjuvant and salvage radiotherapy recommendations. It emphasizes the importance of informed consent and patient education on potential side effects and benefits of radiation therapy.
The new ASTRO white paper recommends 10 fundamental elements for safe and effective IGRT practices, including establishing a multi-professional team and performing end-to-end testing for new procedures. The paper aims to improve the safety and effectiveness of image-guided radiation therapy in radiation oncology.
The ASTRO white paper emphasizes the vital role of patient-specific peer review in improving patient safety and quality of care. The report details suggested targets for peer review throughout various areas within radiation therapy, prioritizing those most likely to impact patient outcomes.
Researchers evaluated CT scans of patients with localized esophageal cancer before and after chemotherapy to identify changes in tumor texture. Smaller change in skewness following chemotherapy was a significant prognostic factor, with median overall survival increasing from 11.1 months to 36.1 months.
This study found that SUVmax is a significant and clinically independent marker for progression-free survival in stage I non-small cell lung cancer (NSCLC) patients. The research included 95 medically inoperable patients who received stereotactic body radiation therapy (SBRT), with median overall survival of 25.3 months and progression...
Research suggests that monitoring hepatic function with HIDA SPECT prior to and during radiation therapy can help tailor treatment plans for unresectable liver cancer patients. This assessment method allows for personalized radiation doses while minimizing the risk of liver injury.
Researchers developed a diffusion abnormality index (DAI) to measure brain tumor response to radiation therapy. The study showed that changes in DAI can predict post-treatment response with high sensitivity and specificity.
Mark P. Carol, MD, a distinguished leader in IMRT and IGRT, has been recognized as ASTRO's 2012 Honorary Member for his groundbreaking approach to developing these techniques. He will be honored at the ASTRO 54th Annual Meeting on October 30, 2012.
Emanuel Hamelburg, a Boston-area prostate cancer survivor, has been recognized for his dedication to cancer awareness and advocacy. He was awarded the Survivor Circle Award by the American Society for Radiation Oncology (ASTRO) in 2012.
Researchers found that adding bavituximab to docetaxel chemotherapy improves response rates, progression-free survival, and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients. The study showed a doubling of the overall response rate compared to the control arm.
Researchers found that standard chemotherapy with paclitaxel, carboplatin, and bevacizumab is equally effective as an experimental regimen in treating advanced non-squamous non-small cell lung cancer. The study suggests that both regimens are tolerable but have different toxicities.
A study of 340 stage III NSCLC patients found that prophylactic cranial irradiation (PCI) significantly reduces the risk of brain metastases, but no improvement in overall survival was observed. The rate of brain metastases for PCI-treated patients was 17.3%, compared to 26.8% for observational arm.
Crizotinib successfully shrinks tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer. The treatment showed a high overall response rate of 60% and improved median progression-free survival.
A study of 168 Stage III NSCLC patients found that married women had the best three-year survival rate of 46 percent, while single men had the worst rate of 3 percent. Married patients generally had improved survival rates compared to single patients, with 33 percent vs. 10 percent.
A study of 14,829 Hispanic lung cancer patients from the California Cancer Registry found that foreign-born Hispanics have an even lower risk of death due to improved socio-economic factors and neighborhood conditions. This contradicts the traditional 'Hispanic paradox' by highlighting the positive impact of social factors on survival.
Patients with stage I non-small cell lung cancer (NSCLC) who received radiation therapy had an increased median survival of 21 months compared to 16 months. The percentage of patients not receiving treatment declined from 20 percent to 16 percent between 1999-2003 and 2004-2008.
A study found that urology-owned radiation oncology practices in Texas increase patients' travel distances by up to three times due to separate treatment centers. This practice model raises concerns about its impact on healthcare costs and patient care.
The American Society for Radiation Oncology (ASTRO) has awarded five physicians with research grants to promote the advancement of radiation therapy. The Junior Faculty Career Research Training Award and Residents/Fellows in Radiation Oncology Research Seed Grant Award support young researchers in radiation oncology, biology, physics, ...
The American Society for Radiation Oncology (ASTRO) has named its 2012 class of Fellows, recognizing their significant contributions to the field of radiation oncology. The new Fellows include renowned experts in research, patient care, education, and leadership.
The Center for Cancer Support and Education in Arlington, Mass., will receive a $10,000 grant from ASTRO's Survivor Circle program to fund breast cancer, advanced cancer, and brain cancer support groups. The Center offers emotional support during treatment and recovery for patients and their family members.
The American Society for Radiation Oncology (ASTRO) has partnered with the Surviving And Moving Forward: The SAMFund for Young Adult Survivors of Cancer to promote cancer survivorship. Through the Survivor Circle exhibit, ASTRO is providing financial assistance and resources to young adult survivors.
The American Society for Radiation Oncology has selected J. Robert Cassady, George T.Y. Chen, and Mark W. Dewhirst as the Society's 2012 Gold Medal recipients for their groundbreaking research, clinical care, teaching, and service in radiation oncology.
Breast cancer patients treated with IMRT had lower incidence of acute and chronic toxicities compared to standard WBI. Larger breasted women also benefited from reduced toxicities with IMRT.
A study found that over 80% of radiation oncologists discuss fertility risks with patients of childbearing age, but many receive inadequate education. The role of radiation oncologists in communicating fertility preservation options is crucial for improving quality of life and care for young cancer patients.
The American Society for Radiation Oncology (ASTRO) has developed a clinical practice guideline for the radiotherapeutic and surgical management of newly diagnosed brain metastases. The guideline provides evidence-based recommendations for choosing treatment modalities based on tumor factors and prognosis.
A study found that intensity modulated radiation therapy (IMRT) improves quality of life among long-term survivors of head and neck cancer. Patients treated with IMRT reported better health-related quality of life compared to those receiving other forms of radiation therapy.
A recent study found that 7% of the US population between ages 14 and 69 has an oral HPV infection, with men being three times more likely to have it than women. The study also revealed that patients infected with oral HPV type 16 have a 14 times greater risk of developing head and neck cancer.